Abstract
The aim of this study was to investigate the disposition of propafenone and its Phase I and II metabolites in relation to kidney function under steady-state conditions. The mechanism of the renal handling of propafenone glucuronides (filtration, secretion) was also examined. Racemic (R/S) propafenone was administered to 7 young volunteers, to 5 older patients with a normal glomerular filtration rate and to 4 patients with chronic renal failure. No difference was found in the plasma concentrations of propafenone and 5-hydroxypropafenone between the three groups. The propafenone glucuronide (PPFG) concentration was elevated in the older compared to the younger subjects (S-PPFG: 544 vs. 222 nmol · ml−1 · mol−1; R-PPFG: 576 vs. 304 nmol · ml−1 · mol−1). Although Glomerular filtration rate did not differ, the renal clearance of propafenone glucuronides was reduced in the former group, which could be attributed to their impaired renal secretion. A dramatic increase in propafenone glucuronide concentration was observed in the patients with renal failure (S-PPFG: 2783 nmol · ml−1 · mol−1; R-PPFG: 7340 nmol · ml−1 · mol−1). In summary, the disposition of propafenone and of its active metabolite 5-hydroxypropafenone was not affected by kidney dysfunction, indicating that no dose adjustment is necessary in patients with renal failure. The accumulation of drug glucuronides in older patients with apparently normal kidney function should be taken into account as a possible factor modifying drug therapy.
Similar content being viewed by others
References
Funck-Brentano C, Kroemer HK, Lee JT, Roden DM (1990) Propafenone. N Engl J Med 322:518–525
Thompson KA, Iansmith DHS, Siddoway LA, Woosley RL, Roden DM (1988) Potent electrophysiologic effects of the major metabolites of propafenone in canine purkinje fibres. J Pharmacol Exp Ther 244:950–955
Malfatto G, Zaza A, Forster M, Sodowick B, Danilo P Jr, Rosen MR (1988) Electrophysiologic, inotropic and antiarrhythmic effects of propafenone, 5-hydroxypropafenone and N-depropylpropafenone. J Pharmacol Exp Ther 246:419–426
Kroemer HK, Turgeon J, Thomas T, Roden DM (1989) Accumulation of propafenone glucuronide during chronic oral therapy (abstract). Clin Pharmacol Ther 45:180
Botsch S, Heinkele G, Meese CO, Eichelbaum M, Kroemer HK (1994) Rapid determination of CYP2D6 phenotype during propafenone therapy by analysing urinary excretion of propafenone glucuronides. Eur J Clin Pharmacol 46:133–135
Tumer N, Scarpace PJ, Lowenthal DT (1992) Geriatric pharmacology: basic and clinical considerations. Ann Rev Pharmacol Toxicol 32:271–302
Cody RJ (1993) Physiological changes due to age-implications for drug therapy of congestive heart failure. Drugs Aging 3:320–334
Kroemer HK, Fromm MF, Bühl K, Terefe H, Blaschke G, Eichelbaum M (1994) An enantiomer-enantiomer interaction of (S)- and (R)-propafenone modifies the effect of racemic drug therapy. Circulation 89:2396–2400
Siddoway LA, Thompson KA, McAllister CB, Wang T, Wilkinson GR, Roden DM, Woosley RL (1987) Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation 75:785–791
Kroemer HK, Mikus G, Kronbach T, Meyer UA, Eichelbaum M (1989) In vitro characterization of the human cytochrome P-450 involved in polymorphic oxidation of propafenone. Clin Pharmacol Ther 45:28–33
Eichelbaum M, Gross AS (1990) The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. Pharmacol Ther 46:377–394
Burgess E, Duff H, Wilkes P (1989) Propafenone disposition in renal insufficiency and renal failure. J Clin Pharmacol 29:112–113
Kroemer HK, Klotz U (1992) Glucuronidation of drugs-a reevaluation of the pharmacological significance of the conjugates and modulating factors. Clin Pharmacokinet 23:292–310
Dawling S, Crome P (1989) Clinical pharmacokinetic considerations in the elderly an update. Clin Pharmacokinet 17:236–263
Reidenberg MM, Camacho M, Kluger J, Drayer DE (1980) Aging and renal clearance of procainamide and acetylprocainamide. Clin Pharmacol Ther 28:732–735
McQuay HJ, Carroll D, Faura CC, Gavaghan DJ, Hand CW, Moore RA (1990) Oral morphine in cancer pain: influences on morphine and metabolite concentration. Clin Pharmacol Ther 48:236–244
Spahn H, Spahn I, Benet LZ (1989) Probenecid-induced changes in the clearance of carprofen enantiomers: a preliminary study. Clin Pharmacol Ther 45:500–505
Notterman DA, Drayer DE, Metakis L, Reidenberg MM (1986) Stereoselective renal tubular secretion of quinidine and quinine. Clin Pharmacol Ther 40:511–517
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Fromm, M.F., Botsch, S., Heinkele, G. et al. Influence of renal function on the steady-state pharmacokinetics of the antiarrhythmic propafenone and its Phase I and Phase II metabolites. Eur J Clin Pharmacol 48, 279–283 (1995). https://doi.org/10.1007/BF00198312
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00198312